POMALYST CAPSULE 2MG

Celgene International Sarl (SWITZERLAND)🇸🇬 Health Sciences Authority

Approval Date: Dec 30, 2014
Approval ID: 066301da69bc23f3
Company: Celgene International Sarl (SWITZERLAND)
Type: Therapeutic

Approval Details

Approval Id: 066301da69bc23f3
Drug Name: POMALYST CAPSULE 2MG
Product Name: POMALYST CAPSULE 2MG
Approval Number: SIN14714P
Approval Date: 2014-12-30
Registrant: BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.
Licence Holder: BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.
Drug Type: Therapeutic
Forensic Classification: Prescription Only
Dosage Form: CAPSULE
Dosage: 4.2 Posology and method of administration Treatment must be initiated and monitored under the supervision of physicians experienced in the management of multiple myeloma. Dosing is continued or modified based upon clinical and laboratory findings (see section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Posology <ul> <li>Pomalidomide in combination with bortezomib and dexamethasone</li> </ul> The recommended starting dose of Pomalyst® is 4 mg orally once daily on Days 1 to 14 of repeated 21-day cycles. Pomalidomide is administered in combination with bortezomib and dexamethasone, as shown in Table 1. The recommended starting dose of bortezomib is 1.3 mg/m2 intravenous or subcutaneous once daily, on the days shown in Table 1. The recommended dose of dexamethasone is 20 mg orally once daily, on the days shown in Table 1. Treatment with pomalidomide combined with bortezomib and dexamethasone should be given until disease progression or until unacceptable toxicity occurs. <img src="/TGIF/Pomalyst-Table1.png" alt="Pomalyst Dosage Table 1" /> Pomalidomide dose modification or interruption To initiate a new cycle of pomalidomide, the neutrophil count must be ≥ 1 x 109/l and the platelet count must be ≥ 50 x 109/l. Instructions on dose interruptions or reductions for pomalidomide-related adverse reactions are outlined in the Table 2 and dose levels are defined in Table 3 below: <img src="/TGIF/Pomalyst-Table2.png" alt="Pomalyst Dosage Table 2" /> <img src="/TGIF/Pomalyst-Table3.png" alt="Pomalyst Dosage Table 3" /> If adverse reactions occur after dose reductions to 1 mg, then the medicinal product should be discontinued. Strong CYP1A2 inhibitors If strong inhibitors of CYP1A2 (e.g. ciprofloxacin, enoxacin and fluvoxamine) are co-administered with pomalidomide, reduce the dose of pomalidomide by 50% (see sections 4.5 and 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Bortezomib dose modification or interruption For instructions on dose interruptions or reductions for bortezomib-related adverse reactions, physicians should refer to bortezomib Package Insert. Dexamethasone dose modification or interruption Instructions on dose interruptions or reductions for low-dose dexamethasone-related adverse reactions are outlined in Tables 4 and 5 below. However, dose interruption or resumption decisions are at the physician’s discretion per Package Insert. <img src="/TGIF/Pomalyst-Table4.png" alt="Pomalyst Dosage Table 4" /> If recovery from toxicities is prolonged beyond 14 days, then the dose of dexamethasone will be resumed at one dose level lower than the previous dose. <img src="/TGIF/Pomalyst-Table5.png" alt="Pomalyst Dosage Table 5" /> Dexamethasone should be discontinued if the patient is unable to tolerate 8 mg if ≤ 75 years old or 4 mg if > 75 years old. In case of permanent discontinuation of any component of the treatment regimen, continuation of the remaining medicinal products is at the physician’s discretion. <ul> <li>Pomalidomide in combination with dexamethasone</li> </ul> The recommended starting dose of Pomalyst® is 4 mg orally once daily on Days 1 to 21 of each 28-day cycle. The recommended dose of dexamethasone is 40 mg orally once daily on Days 1, 8, 15 and 22 of each 28-day cycle. Treatment with pomalidomide combined with dexamethasone should be given until disease progression or until unacceptable toxicity occurs. Pomalidomide dose modification or interruption Instructions for dose interruptions or reductions for pomalidomide-related adverse reactions are outlined in Table 2 and 3. Dexamethasone dose modification or interruption Instructions for dose modification for dexamethasone-related adverse reactions are outlined in Table 4. Instructions for dose reduction for dexamethasone-related adverse reactions are outlined in Table 6 below. However, dose interruption / resumption decisions are at physician’s discretion per the current Package Insert. <img src="/TGIF/Pomalyst-Table6_220921.png" alt="Pomalyst Dosage Table 6" /> Dexamethasone should be discontinued if the patient is unable to tolerate 10 mg if ≤ 75 years old or 8 mg if > 75 years old. Special populations Elderly <ul> <li>Pomalidomide in combination with bortezomib and dexamethasone</li> </ul> No dose adjustment is required for pomalidomide. For information on bortezomib given in combination with Pomalyst®, refer to the respective current Package Insert. For patients >75 years of age, the starting dose of dexamethasone is: <ul> <li>For Cycles 1 to 8: 10 mg once daily on Days 1, 2, 4, 5, 8, 9, 11 and 12 of each 21-day cycle</li> <li>For Cycles 9 and onwards: 10 mg once daily on Days 1, 2, 8 and 9 of each 21-day cycle.</li> </ul> <ul> <li>Pomalidomide in combination with dexamethasone</li> </ul> No dose adjustment is required for pomalidomide. For patients > 75 years of age, the starting dose of dexamethasone is: <ul> <li>20 mg once daily on days 1, 8, 15 and 22 of each 28-day cycle.</li> </ul> Renal impairment No dose adjustment of pomalidomide is required for patients with renal impairment. On haemodialysis days, patients should take their pomalidomide dose following haemodialysis. Hepatic impairment Patients with serum total bilirubin > 1.5 x ULN (upper limit of normal range) were excluded from clinical studies. Hepatic impairment has a modest effect on the pharmacokinetics of pomalidomide (see section 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). No adjustment of the starting dose of pomalidomide is required for patients with hepatic impairment as defined by the Child-Pugh criteria. However, patients with hepatic impairment should be carefully monitored for adverse reactions and dose reduction or interruption of pomalidomide should be used as needed. Paediatric population There is no relevant use of Pomalyst® in children aged 0–17 years for the indication of multiple myeloma. Method of administration Oral use. Pomalyst® should be taken orally at the same time each day. The capsules should not be opened, broken or chewed (see section 6.6 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). This medicinal product should be swallowed whole, preferably with water, with or without food. If the patient forgets to take a dose of Pomalyst® on one day, then the patient should take the normal prescribed dose as scheduled on the next day. Patients should not adjust the dose to make up for a missing dose on previous days. It is recommended to press only on one end of the capsule to remove it from the blister thereby reducing the risk of capsule deformation or breakage. For information on other medicinal products given in combination with Pomalyst®, refer to the respective current Package Insert.
Route Of Administration: ORAL
Indication Info: 4.1 Therapeutic indications Pomalyst® in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide. Pomalyst® in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.
Contraindications: 4.3 Contraindications <ul class="dash"> <li>Pregnancy.</li> <li>Women of childbearing potential, unless all the conditions of the pregnancy prevention programme are met (see sections 4.4 and 4.6 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).</li> <li>Male patients unable to follow or comply with the required contraceptive measures (see section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).</li> <li>Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.</li> </ul> For information on other medicinal products given in combination with Pomalyst®, refer to the respective current Package Insert.
Atc Code: L04AX06
Atc Item Name: pomalidomide
Pharma Manufacturer Name: CELGENE PTE. LTD.

Active Ingredients

POMALIDOMIDE

2 mg

POMALIDOMIDE

2 MG

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

Dec 30, 2014

Approval ID

066301da69bc23f3

Type

Therapeutic

Back to HSA Approvals